Israel's Innovation Authority and Ministry of Health have launched a regulatory sandbox for artificial intelligence in healthcare, testing autonomous and semi-autonomous medical systems in real clinical settings. The first cohort includes three Israeli health technology companies developing AI applications for pregnancy care, heart failure management, and fetal ultrasound assessment.
Most medical AI to date has supported clinicians: flagging suspicious radiology images, highlighting risk factors, or helping interpret data. The Israeli sandbox targets the next stage - systems that may independently perform parts of a clinical workflow, make recommendations under predefined protocols, or reduce the need for physician review of every routine output. That shift raises sharper regulatory questions: Who is accountable when an algorithm acts? How much human oversight is sufficient? What evidence demonstrates safety across different patient groups and care settings?
A regulatory sandbox is not a relaxation of standards. It is a structured environment where companies, hospitals, and regulators can test technologies that do not fit neatly within existing rules. Israel's version aims to identify regulatory barriers, evaluate safety and effectiveness, generate clinical evidence, and establish adoption pathways for domestic and international markets. For a small but highly digitized healthcare system with a strong healthtech sector, this allows regulators to observe technologies in practice rather than write rules in the abstract.
Three companies, three regulatory questions
Pulsenmore will work with Rabin Medical Center's Beilinson Hospital on an AI system for analyzing at-home ultrasound examinations performed by pregnant women. The long-term regulatory question is whether such a system could make autonomous clinical determinations for routine scans without physician interpretation of every exam. Pulsenmore says its home ultrasound platform has already supported more than 250,000 home scans, creating a substantial real-world dataset for developing and validating AI applications.
Cordio Medical will pilot an AI-enabled heart failure management system with Tel Aviv Sourasky Medical Center. The system combines voice analysis, questionnaires, smartphone data, smartwatch data, and electronic medical record information to detect early clinical deterioration and recommend medication adjustments according to a protocol defined by the treating physician. This moves AI beyond passive monitoring into therapeutic intervention support, raising questions about explainability, escalation, physician control, and the boundary between clinical advice and automated care.
Simahook will work with Hadassah Ein Kerem and Hadassah Mount Scopus medical centers on an AI-guided fetal weight assessment system. The regulatory issue here is partly task-shifting: if intelligent guidance allows a broader group of healthcare professionals to perform ultrasound assessments safely and accurately, it could help address workforce shortages. Any expansion of who performs a clinical task must be supported by evidence around training, competency, quality assurance, and diagnostic reliability.
Lifecycle regulation is the emerging standard
Canada offers a parallel. Health Canada has issued guidance for machine learning-enabled medical devices, setting expectations for design, risk management, data selection, development and training, testing and evaluation, clinical validation, transparency, and post-market monitoring. The Canadian framework also incorporates a predetermined change control plan - a mechanism to manage planned future changes to machine learning systems while maintaining regulatory oversight. This reflects a common challenge: AI-enabled medical devices may need to evolve after approval, but uncontrolled evolution is incompatible with patient safety.
Traditional medical devices are relatively stable once marketed. AI software can change through retraining, updates, expanded datasets, or adaptation to new clinical environments. The evidence package must therefore extend beyond initial performance claims. Regulators need to know how performance will be monitored, how drift will be detected, what changes are permitted, when new review is required, and how users will be informed.
In Europe, the EU AI Act entered into force in 2024 and applies a risk-based framework. AI systems used as medical devices or as safety components of regulated medical devices are generally treated as high-risk, creating obligations around data governance, technical documentation, human oversight, transparency, and post-market monitoring - in addition to existing medical device requirements. For companies seeking global markets, clinical evidence, quality systems, and AI governance must be designed with multiple regulatory regimes in mind from the outset.
Israel's sandbox should be seen less as a local experiment and more as part of a global regulatory learning process. Its value will depend on whether the pilots generate transferable evidence: how autonomy is defined, how risks are controlled, how clinicians interact with AI outputs, how patients understand automated care, and how responsibility is allocated when decisions are shared between software and professionals. For healthcare professionals tracking this space, the shift toward autonomous systems has direct implications for workflow, liability, and training - areas where AI for Healthcare resources are increasingly relevant. Those in regulatory roles may find the evolving frameworks worth studying through structured programs like AI for Regulatory Affairs Specialists.
Why this matters for healthcare professionals
The Israeli sandbox signals that autonomous medical AI is moving from concept to clinical deployment. For clinicians, this means routine tasks like ultrasound analysis, fetal weight assessment, and heart failure monitoring may soon be partially automated - changing how work is distributed across care teams. The regulatory frameworks being tested now will determine the degree of human oversight required, who bears accountability for algorithmic decisions, and what evidence standards apply. Understanding these developments early matters because they will shape clinical practice, liability structures, and professional roles in the coming years.
Your membership also unlocks:
